<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="http://dx.doi.org/10.17917/YTHD-KF51" scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><p><b>Protocol Type:</b> in vitro assay</p><p><b>Protocol Name:</b> NCL Method ITA-3: Mouse Granulocyte-Macrophage Colony-Forming Unit Assay</p><p><b>Protocol Abbreviation:</b> ITA-3</p><p><b>Protocol Version:</b> 4<hr><p><b>DOI:</b> <a href = http://dx.doi.org/10.17917/YTHD-KF51>http://dx.doi.org/10.17917/YTHD-KF51</a></p><p><b>Protocol File:</b> protocols/20240410_19-05-34-575_NCL_Method_ITA-3.pdf<p><b>File Title:</b> ITA-3</p><p><b>Description:</b></b> Myelosuppression is a common dose limiting toxicity of cytotoxic oncology drugs. Nanoparticles may distribute to bone marrow and/or release drug that is delivered to bone marrow. Therefore, understanding potential toxicity of nanoparticles or drugs which nanoparticles carry is an important step in preclinical safety evaluation. The protocol described here details the in vitro CFU-GM study.<hr><p><b>Resource Type:</b>  Protocol</p><p><b>Data Access:</b> <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a><p></body></html>